Please assess the completion status of the following clinical trial:

Trial Title: Radiographic Analysis Using PureGen Versus Autologous Bone in Posterolateral Fusion (PLF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Symptomatic lumbar degenerative disc disease in up to two contiguous levels between L1 and S1~* Subjects with back and/or leg pain indicated for posterior stabilization with or without decompression at any level and posterolateral fusion (PLF)~* Unresponsive to conservative treatment for at least 6 months~* Radiographic evidence of primary diagnosis~Exclusion Criteria:~* More than 2 levels requiring posterolateral fusion~* Spondylolisthesis greater than Grade I~* Prior failed fusion surgery at any lumbar level(s)~* Systemic or local infection in the disc or cervical spine, past or present~* Active systemic disease~* Osteoporosis, osteomalacia, or other metabolic bone disease that would significantly inhibit bone healing~* Use of other bone graft, Bone Morphogenetic Protein (BMP) or bone graft substitutes in addition to or in place of those products specified~* BMI greater than 40~* Use of post operative Spinal Cord Stimulator (SCS)~* Known or suspected history of alcohol and/or drug abuse~* Involved in pending litigation or worker's compensation related to the spine~* Pregnant or planning to become pregnant during the course of the study~* Insulin-dependent diabetes mellitus~* Life expectancy less than duration of study~* Any significant psychological disturbance that could impair consent process or ability to complete self-assessment questionnaires~* Undergoing chemotherapy or radiation treatment, or chronic use of oral or injected steroids or prolonged use of non-steroidal anti-inflammatory drugs.~* Known history of hypersensitivity or anaphylactic reaction to dimethyl sulfoxide (DMSO)

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Study Graft Composite (Type: EXPERIMENTAL): AlphaGraft ProFuse Demineralized Bone Scaffold are soaked in PureGen according to Preparation for Use and handling technique. The graft composite is placed on the randomized study side contralateral to the autograft bone graft per surgeon's standard technique for PLF. The wound is closed according to surgeon's standard technique.~Post operative care will be according to the site specific standard of care. An avoidance of heavy physical activity and limitations on working, lifting, bending etc. are common precautions post procedure. The decision to use a post operative orthosis is left to the discretion of the Investigator.
- Control Graft Composite (Type: ACTIVE_COMPARATOR): Contralateral to the study graft composite, placement of posterolateral fusion graft composite containing iliac crest bone (5 cc/level/side) and local autograft composite (equal volume split with study side). Supplemental posterior pedicle screw fixation utilizing Zodiac, Illico or Xenon Spinal Fixation system.~* A defined volume of iliac crest bone graft (indicated in table 2) is harvested and combined with 50% of the previously harvest morselized local bone~* The graft composite is placed on the randomized control side using standard technique for PLF

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility